Clinical trial
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone…
NCT00103168 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00103168 |
|---|---|
| Title | Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor |
| Official title | Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib Mesylate (Glivec) Versus No Further Therapy After Complete Surgery |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Collaborators | Italian Sarcoma Group UNICANCER Grupo Espanol de Investigacion en Sarcomas |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 908 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Sep 1, 2017 |
| First posted | Feb 8, 2005 |
| Last update posted | Jul 9, 2018 |
| Countries | Australia, Denmark, France, Germany, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: